GRIM-19蛋白在非小细胞肺癌组织中的表达及其临床意义  

Expression and clinical significance of GRIM-19 in non-small cell lung cancer

作　　者：周爱民[1,2] 赵继京[1] 叶静[1] 肖卫华[3] Dhananjaya V.KalvakolanU 刘荣玉[1] 

机构地区：[1]安徽医科大学第一附属医院干部呼吸内科,安徽合肥230022 [2]安徽中医药高等专科学校医疗系,安徽芜湖241000 [3]中国科技大学生命科学学院,安徽合肥230027 [4]University of Maryland School of Medicine

出　　处：《癌症》2009年第4期431-435,共5页Chinese Journal of Cancer

基　　金：国家自然科学基金(No.30670936)~~

摘　　要：背景与目的:维甲酸/干扰素联合应用诱导细胞凋亡相关的基因(gene associated with retinoid-interferon-induced mortality-19,GRIM-19)是死亡相关基因中的一员,它的过高表达可以抑制肿瘤细胞的增殖,促进细胞的凋亡。本研究检测非小细胞肺癌和正常肺组织中GRIM-19蛋白的表达和定位,探讨其在非小细胞肺癌组织中表达的临床意义。方法:应用免疫组化ABC法检测49例非小细胞肺癌组织及相应癌旁正常组织中GRIM-19蛋白的表达情况,并用光密度(A)值定量描述其表达水平;同时用激光共聚焦扫描技术检测GRIM-19蛋白在细胞内的定位。结果:正常肺组织中GRIM-19主要定位于细胞浆中;而肿瘤组织主要位于细胞核中。激光共聚焦扫描技术检测验证了这种结果。GRIM-19蛋白在正常肺组织中阳性率为93.8%(46/49),而在非小细胞肺癌中阳性率为55.1%(27/49),两者之间的差异有统计学意义(P<0.01)。肿瘤组织中GRIM-19蛋白的平均表达水平(A值为0.22±0.01)比正常组织(A值为0.29±0.02)下降24.3%(P<0.01)。GRIM-19蛋白阳性率在Ⅰ、Ⅱ、Ⅲ+Ⅳ期非小细胞肺癌组织中分别是78.6%、48.1%、12.5%,其差异有统计学意义(rs=-0.428,P<0.05)。结论:肺癌组织中GRIM-19蛋白表达随肿瘤恶性程度升高而显著下降甚至缺失,分布由胞浆转入细胞核;GRIM-19蛋白表达可能与肺癌的发生发展相关。Background and Objective. Gene associated with retinoidinterferon-induced mortality-19 （GRIM-19） is one of the death-related genes. Its overexpression could suppress proliferation and promote apoptosis of tumor cells. This study was to investigate the expression and clinical significance of GRIM-19 in primary non-small cell lung cancer （NSCLC）. Methods：The expression of GRIM-19 in 49 specimens of NSCLC with corresponding adjacent normal lung tissues was examined by immunohistochemistry. The cellular distribution of GRIM-19 was observed under laser scanning confocal microscope. Results.GRIM-19 was dominantly located in the cytoplasm of normal lung cells but enriched in the nuclei of cancer cells. The result was verified by laser scanning confocal microscopy. The positive rate of GRIM-19 was significantly higher in normal lung tissues than in NSCLC （93.8% vs. 55.1%, P〈0.05）. The protein level of GRIM-19 in NSCLC was reduced by 24.3% of that in normal lung tissues （0.22±0.01 vs. 0.29±0.02, P〈0.05）. The positive rates of GRIM-19 were 78.6% in stage Ⅰ NSCLC, 48.1% in stage Ⅱ NSCLC, and 12.5% in stages Ⅲ-Ⅳ NSCLC. The expression of GRIM-19 was negatively correlated to clinical stage （r,=-0.428, P〈0.05）. Conclusion： GRIM-19 expression is down-regulated along the clinical development of NSCLC, and transfers from cytoplasm to nucleus.

关 键 词：GRIM-19蛋白 肺肿瘤 癌 非小细胞性 免疫组化 激光共聚焦显微镜 抑制基因 

分 类 号：R734.2[医药卫生—肿瘤]